Compare REX AI Equity Premium Income ETF (AIPI) vs Danaher Corporation (DHR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
REX AI Equity Premium Income ETF vs Danaher Corporation — how do they compare? REX AI Equity Premium Income ETF trades at $36.35, while Danaher Corporation trades at $190.62 (market cap $137.44B). The key difference: Danaher Corporation pays a 0.82% dividend while REX AI Equity Premium Income ETF pays none. Which is the better fit depends on your goals.
| AIPI | DHR | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $44.93 | $242.05 |
52-Week Low | $32.45 | $161.91 |
Market Cap | — | $137.44B |
Enterprise Value | — | $150.22B |
Dividend Yield | — | 0.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AIPI trades at $37.10, up 1.87% with neutral technical signals. The ETF maintains a high weekly dividend distribution strategy, recently transitioning to weekly payouts. Technical analysis shows mixed signals with bullish moving averages but neutral oscillators, trading near key support at $37. Recent news highlights concerns about NAV erosion risk despite the attractive yield structure.
The outlook remains cautious due to structural limitations in the option-writing strategy that caps upside potential. While the ~34.8% yield appears attractive, sustainability depends heavily on AI market momentum. Investors face NAV erosion risk if technology sector performance falters, requiring careful monitoring of the fund's premium income strategy effectiveness.
Danaher (DHR) trades at $190.77, down 1.47% on the day, with a bullish technical outlook supported by moving averages and strong institutional support. The company maintains solid fundamentals with consistent earnings beats, a 14.89% net income margin, and positive cash flow of $2.54B in 2025. Recent developments include the Masimo acquisition approval and new product launches in the biotechnology segment.
The stock presents a compelling opportunity with 69% analyst buy ratings and a $214.73 price target suggesting 12.6% upside. Key risks include revenue stagnation from $24.6B in 2025 to projected $24.8B in 2026 and the recent $172.5M legal settlement over pandemic-era disclosures. Biotechnology segment growth at 7% remains a positive catalyst.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About REX AI Equity Premium Income ETF
AIPI provides exposure to leading artificial intelligence firms while seeking to generate monthly income. It uses a covered call strategy to capture premiums from the volatility of AI-related stocks.
Read more on AIPI →About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →
